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Introduction: Docetaxel, cisplatin plus 5-FU (DCF) regimen is a use-
ful chemotherapy against malignant diseases such as advanced head 
and neck cancer. However, DCF regimen is sometimes withdrawn by 
severe myelosuppression and nonhematologic toxic effects, includ-
ing mucositis. Previous animal and clinical studies showed that the 
degrees of docetaxel-, cisplatin-, and 5-FU–induced toxicities depend 
on their dosing time. We have reported that the frequency of doc-
etaxel-induced intestinal mucositis was greater after dosing at an 
active phase than at an inactive phase in mice. The aim of the present 
study was to determine the influence of dosing schedule of DCF regi-
men on chemotherapy-induced toxicities in clinical practice.
Patients (or Materials) and Methods: Patients with oral squamous 
cell carcinoma treated with DCF regimen were randomly allocated 
to the following 2 groups: chemotherapy started from morning 
(10:30) in the first group and evening (18:30) in the second group. 
Hematologic and nonhematologic adverse effects were assessed for 
14 days after the start of chemotherapy.
Results: The most frequently observed mild to severe adverse effects 
were neutropenia, diarrhea, stomatitis, and nausea. The frequency 
of grade 3 to 4 neutropenia was 62.5% (5 of 8) in the morning 
group and 28.6% (2 of 7) in the evening group. Grade 3 to 4 event 
of stomatitis and grade 3 event of nausea were more detected in the 
morning group.
Conclusion: These findings suggest that chronotherapy of DCF 
regimen might diminish severe adverse effects in patients with oral 
squamous cell carcinoma.
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Introduction: This pilot study, within the ARITMO project, evalu-
ated the population exposure to antipsychotics (APs: ATC group 
N05A, excluding lithium) with proarrhythmic risk, by analyzing the 
FDA Database (FDA_AERS) and European drug utilization data (12 
countries).
Patients (or Materials) and Methods: Cases of QT prolongation and 
torsades de pointes (TdP) associated with APs were retrieved from 
the FDA_AERS (2004–2011) database. APs with unexpected signals 
were defined by disproportionality (Reporting Odds Ratio [ROR], 
with 95% CI > 1, cases > 3) and checking in Arizona_CERT (www.
azcert.org). Consumption data (2006–2010) were provided from 
administrative databases from 12 European countries. Data were 
expressed as DDDs/TID (defined daily doses per thousand inhabit-
ants per day).
Results: Thirty-one APs were reported in 1467 cases of TdP/QT 
prolongation, with 10 unexpected signals: amisulpride (ROR = 25.0; 
95%CI, 17.6–35.6), aripiprazole (1.7; 1.3–2.2), bromperidol (88.4; 
37.7–207.9), chlorprothixene (10.7; 3.9–29.0), cyamemazine (7.6; 
4.3–13.5), fluphenazine (7.9; 3.9–16.0), levomepromazine (5.2; 2.3–
11.6), olanzapine (4.7; 4.1–5.3), prothipendyl (21.0; 10.7–41.4), and 
zuclopenthixol (14.9; 6.9–31.8). In all countries, AP use increased 
over 5 years from only +0.35 DDD/TID (Norway) to +11.01 (Serbia, 
preliminary data). The atypical/typical ratio increased in line with 
expectations. There was variable AP utilization in 2010, from 5.04 
(Estonia) to 16.57 (Serbia, preliminary data). The mean use of 
APs with unexpected signals ranged from 1.72 (Estonia) to 5.45 
(Slovenia). Olanzapine was stable but widely used and peaked at 
2.9 in Norway. Aripiprazole utilization generally increased. There 
appeared to be substantial utilization of fluphenazine in Serbia (3.77 
in 2010) and cyamemazine in France (2.81 in 2009).
Conclusion: Different exposure to AP use among countries implies 
different levels of population risk. The use of atypical APs is growing 
(eg, aripiprazole). Olanzapine should be monitored by regulators, 
due to its appreciable utilization in most countries. Fluphenazine 
and cyamemazine are specific concerns in Serbia and France, respec-
tively. The study also demonstrates the synergy between drug utili-
zation and adverse event databases to alert health policy personnel 
of potential future activities to reduce ADRs, especially from drugs 
with unexpected signals. As a result, help promote higher standards 
of prescribing in the future.
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Introduction: We report a case of digoxin intoxication with severe 
visual symptoms.
Patients (or Materials) and Methods: Digoxin 0.25 mg QD for atrial 
fibrillation was prescribed to a 91-year-old woman with an estimated 
creatinine clearance of 18 mL/min. Within 2 to 3 weeks, she devel-
oped nausea, vomiting, and dysphagia, and began complaining of 
snowy and blurry vision, photopsia, dyschromatopsia, aggravated 
bedtime visual and proprioceptive illusions (she felt as being on a 
boat), and colored hallucinations. She consulted her family doctor 
twice and visited the eye clinic once until, 1 month after starting 
digoxin, impaired autonomy led her to be admitted to the emergency 
department.
Results: Digoxin intoxication was confirmed by a high plasma level 
measured on admission (5.7 µg/L; reference range, 0.8-2 µg/L). After 
stopping digoxin, general symptoms resolved in a few days, but 
visual symptoms persisted. Ophtalmologic care and follow-up diag-
nosed digoxin intoxication superimposed on pre-existing left eye 
(LE) cataract, dry age-related macular degeneration (DMLA), and 
Charles Bonnet syndrome. Visual acuity was 0.4 (right eye, RE) 
and 0.5 (LE). Ocular fundus was physiologic except for bilateral 
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dry DMLA. Dyschromatopsia was confirmed by poor results on 
Ishihara test (1/13 OU). Computerized visual field results revealed 
nonspecific diffuse alterations. Full-field electroretinogram (ERG) 
showed moderate diffuse rod and cone dysfunction. Visual symp-
toms progressively improved over the next 2 months, but ERG did 
not. Complete resolution was not expected due to the pre-existing 
eye disease. The patient was finally discharged home after a 5-week 
hospital stay.
Conclusion: Digoxin intoxication can go unrecognized by clinicians, 
even in a typical presentation. The range of potential visual symp-
toms is far greater than isolated xanthopsia (yellow vision) classically 
described in textbooks. Newly introduced drugs and all symptoms 
must be actively sought after, because they significantly affect quality 
of life and global functioning, especially in the elderly population, 
most liable not to mention them.
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Introduction: Worldwide data indicate that antibiotics are frequently 
used inappropriately. Inappropriate use of antibacterial agents may 
lead not only to unfavorable medical consequences but also to sub-
stantial ecological and economic consequences. The objective of this 
study was to investigate the extent of storage and wastage of antibac-
terial agents in households in Novi Sad, Serbia.
Patients (or Materials) and Methods: The study was performed in an 
8-month period (December 2011–July 2012) among households in 
Novi Sad, Serbia. The households were randomly selected from the 
telephone directory. The investigator informed the respondents about 
the aim of the study and asked if they agreed to participate. After 
that, the interviewer performed the survey by visited each household. 
During the visit, the presence or absence of antibiotics was checked, 
and the respondent was interviewed.
Results: The total number of antibacterial agents in the 383 surveyed 
households was 318, constituting 7.3% of the total stored medica-
tions. From 383 families included in the study, antibiotics were found 
in 178 (46.5%). In 13 (7.3%) families were found > 1 pack of the 
same antibiotics. The median number of antibacterial agents per 
household was 1 (range, 1-5). The most common antibacterial agents 
encountered were cephalexin (21.4%) and amoxicillin (18.8%), fol-
lowed by doxycycline, amoxicillin/clavulanic acid, and sulfameth-
oxazole/ trimethoprim (10.1%). There was no statistically significant 
difference in the number of antibacterial agents between families with 
or without children under 12 years in the family (P = 0.218). The 
number of family members and the number of medications in the 
family were significantly and positively (P = 0.014 and P < 0.001, 
respectively) correlated with the number of antibacterial agents found 
in the households. Wasted antibacterial agents, defined as those that 
had expired, were 20.8%. The percentage of antibacterial agents 
that were not currently in use was 85.2%. Estimated total value of 
antibacterial agents found in the study was 892.52€ , approximately 
2.33€ per household. The total wastage of antibacterial agents was 
valued at 166.97€ , approximately 0.44€ per household.
Conclusion: Antibacterial agents were commonly encountered in 
Serbian households, and a relatively large percentage was being 
wasted. Informational and educational activities aimed at improv-
ing the public’s knowledge about antimicrobials play the leading role 
in reducing imprudent use of antibiotics.
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Introduction: Atypical antipsychotics (AP) are increasingly being 
used in children and adolescents for the treatment of psychiatric 
disorders such as psychoses, autism, attention-deficit/hyperactivity 
disorder (ADHD), and aggressive behavior. Atypical AP may cause 
QT prolongation on the electrocardiogram (ECG), which predisposes 
patients to an increased risk of developing threatening ventricular 
arrhythmias. Although this phenomenon has been exhaustively 
reported in adults, few studies investigated the safety of these drugs 
in pediatric patients.
Patients (or Materials) and Methods: We performed an open-label, 
prospective study to assess the arrhythmic risk of aripiprazole and 
risperidone in pediatrics. A total of 60 patients (55 M/5 F; mean age, 
11.8 [3.27] years; range, 3–17 years), receiving a new prescription of 
aripiprazole or risperidone in monotherapy underwent a standard 
ECG before and after 2 months from the beginning of antipsychotic 
treatment. Basal and posttreatment ECG parameters, including mean 
QT (QTc) and QT dispersion (QTd) interval duration, were com-
pared within treatment groups.
Results: Twenty-nine patients were treated with aripiprazole (mean 
dosage, 7.8 [3.2] mg/d) and 31 with risperidone (mean dosage, 1.7 
[1.1] mg/d). Although no patients exhibited pathologic values of QTc 
or QTd, treatment with risperidone was associated with a significant 
increase of both QTc and QTd values (407.4 [11.9] ms vs 412.4 
[10.3] ms, P = 0.03; and 40.0 [4.4] ms vs 44.7 [5.5] ms, P = 0.0001, 
respectively). Conversely, treatment with aripiprazole was associated 
with a statistically significant increase of QTd (40.6 [6.5] ms vs 46.3 
[7.2] ms, P = 0.0001) in presence of an unmodified QTc. Moreover, 
in patients treated with aripiprazole, a significant decrease in heart 
rate was observed after treatment (90.0 [21.2] beats/min vs 79.8 
[19.3] beats/min; P = 0.0003).
Conclusion: The present study provided important advances in the 
assessment of the cardiologic safety of second-generation AP dur-
ing the pediatric age. Indeed, the treatment with risperidone and 
aripiprazole was associated with modifications of the QT tract on 
ECG, thus indicating that these drugs can exert a substantial effect on 
the ventricular repolarization. Our study remarks the importance to 
perform an ECG examination in all patients undergoing AP therapy. 
Both QTc and QTd evaluation should be performed to warranty 
a reliable assessment of drug-induced QT prolongation. Caution 
should also be exercised in prescribing aripiprazole in patients at 
risk of bradycardia.
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